1,768 results on '"Czernin, Johannes"'
Search Results
252. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.
253. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.
254. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
255. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
256. The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study.
257. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
258. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort.
259. STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging.
260. The Disappearing Act of Nuclear Medicine in The Netherlands: Just a New Trick by the Great Harry Houdini?
261. Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection : A Multicenter Prospective Phase 3 Imaging Trial
262. Immune-Checkpoint Blockade Enhances ²²⁵Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
263. Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer : An international, multicentre, retrospective study
264. 2022 INTERNATIONAL SURVEY ON THE STATUS OF PROSTATE CANCER THERANOSTICS.
265. Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis.
266. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with 2 metastatic castration-resistant prostate cancer (RECIP 1.0): 3 an international multicenter study.
267. PET/CT in Oncology: Current Status and Perspectives
268. Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?
269. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
270. Validation of FAPi PET biodistribution by immunohistochemistry in patients with solid cancers: A prospective exploratory study.
271. Reply: PSMA-Targeted Therapeutics: A Tale About Law and Economics
272. Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).
273. Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study.
274. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
275. 68Ga-FAPI-46 and 18F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors
276. Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress
277. The future of hybrid imaging—part 3: PET/MR, small-animal imaging and beyond
278. The future of hybrid imaging—part 2: PET/CT
279. The future of hybrid imaging—part 1: hybrid imaging technologies and SPECT/CT
280. The Impact of Fluorodeoxyglucose–Positron Emission Tomography in Primary Staging and Patient Management in Lymphoma Patients
281. Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism
282. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study
283. Respiratory gated pet derived in a fully automated manner from raw pet data
284. Radiation Dose Estimates for [18F]5-Fluorouracil Derived from PET-Based and Tissue-Based Methods in Rats
285. Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors
286. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
287. A Conversation Between Hong Wu and Johannes Czernin
288. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI in the detection, intra-prostatic localization, and local extension of primary prostate cancer: A single-center imaging study with histopathology gold-standard.
289. Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245.
290. Impact of PSMA PET/CT on SRT planning: Preliminary results from the randomized phase III trial NCT03582774.
291. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
292. Reply: Radioguided Surgery
293. The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
294. The Replication Stress Response Kinase ATR is an Interferon Signaling Driven Co-Dependency In Pancreas Cancer Cells
295. Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study
296. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
297. Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?
298. Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism
299. Efficacy and Safety of ¹⁷⁷Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement : A Multicenter Retrospective Study
300. Impact of PSMA PET/CT on SRT planning: Preliminary results from a randomized phaseIII trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.